Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caplacizumab Safety and PK/PD in Japanese and White Healthy Volunteers
NCT03172208Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jun 2017
- Primary completion
- Oct 2017
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of caplacizumab in thrombotic thrombocytopenic purpura (TTP) (12 arms), sponsored by Sanofi. Primary endpoint: Number of treatment-emergent adverse events at Day 34. Started Jun 2017; status: completed.
02
Drugs
caplacizumab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on NCT03172208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03172208.